论文部分内容阅读
目的对纤溶酶联合血栓通在缺血性脑卒中治疗中的应用效果进行分析。方法 98例缺血性脑卒中患者,随机分为对照组与观察组,各49例,在对症支持治疗基础上对照组给予纤溶酶治疗,观察组给予纤溶酶联合血栓通治疗,对比两组治疗效果与不良反应。结果两组患者治疗期间均无明显不良反应发生(P>0.05),观察组治疗总有效率显著高于对照组,差异有统计学意义(P<0.05);经对比,两组患者治疗后神经功能缺损评分均显著低于治疗前,且观察组神经功能缺损评分显著低于对照组,差异均有统计学意义(P<0.05)。结论纤溶酶联合血栓通在缺血性脑卒中治疗中疗效显著,可有效改善患者神经功能缺损症状,大大提高患者生活质量,值得在临床中推广。
Objective To analyze the effect of thrombolytic combined with thrombosis in the treatment of ischemic stroke. Methods 98 cases of ischemic stroke patients were randomly divided into control group and observation group, 49 cases in each group. On the basis of symptomatic supportive therapy, the control group was treated with plasmin, the observation group was given plasminogen combined with Xueshuantong treatment, Treatment effect and adverse reactions in group. Results There was no significant adverse reaction during the treatment in both groups (P> 0.05). The total effective rate in the observation group was significantly higher than that in the control group (P <0.05). After the comparison, The scores of functional impairment were significantly lower than before treatment, and the score of neurological deficit in observation group was significantly lower than that of control group (P <0.05). Conclusion The combination of thromboplastin and thrombosis has significant curative effect in the treatment of ischemic stroke, which can effectively improve the symptoms of neurological deficits and greatly improve the quality of life of patients, which is worth to be popularized clinically.